Urovant Sciences Ltd (NASDAQ:UROV) – Equities researchers at SunTrust Banks lowered their Q3 2020 EPS estimates for Urovant Sciences in a report issued on Wednesday, November 6th. SunTrust Banks analyst J. Lee now expects that the company will post earnings of ($1.02) per share for the quarter, down from their prior estimate of ($0.98). SunTrust Banks also issued estimates for Urovant Sciences’ Q4 2020 earnings at ($1.07) EPS, FY2020 earnings at ($3.88) EPS and FY2021 earnings at ($3.62) EPS.
Urovant Sciences (NASDAQ:UROV) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.30.
UROV has been the topic of several other reports. ValuEngine lowered Urovant Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. HC Wainwright set a $28.00 price objective on Urovant Sciences and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Zacks Investment Research lowered Urovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $21.44.
Shares of NASDAQ UROV traded down $0.34 during midday trading on Friday, hitting $9.62. The stock had a trading volume of 51,500 shares, compared to its average volume of 55,316. The company has a market capitalization of $293.09 million, a price-to-earnings ratio of -2.19 and a beta of 1.66. Urovant Sciences has a 1-year low of $4.05 and a 1-year high of $14.49. The company has a quick ratio of 6.20, a current ratio of 6.20 and a debt-to-equity ratio of 0.29. The company has a fifty day moving average price of $9.64 and a 200 day moving average price of $8.56.
Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. acquired a new position in Urovant Sciences during the 1st quarter worth approximately $49,000. Northern Trust Corp lifted its position in Urovant Sciences by 55.8% during the 2nd quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock worth $136,000 after acquiring an additional 6,144 shares in the last quarter. First Trust Advisors LP acquired a new position in Urovant Sciences during the 3rd quarter worth approximately $163,000. Marshall Wace LLP acquired a new position in shares of Urovant Sciences in the 1st quarter valued at approximately $325,000. Finally, LVW Advisors LLC acquired a new position in shares of Urovant Sciences in the 3rd quarter valued at approximately $372,000. 24.23% of the stock is currently owned by hedge funds and other institutional investors.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Further Reading: Capital Gains Distribution
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.